Lakefront Biotherapeutics (LKFT) Other Non-Current Liabilities (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Other Non-Current Liabilities for 13 consecutive years, with $15.7 million the latest figure, recorded in Q1 2026.

• Quarterly Other Non-Current Liabilities fell 49.08% year-over-year to $15.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.7 million (down 49.08% YoY) and the FY2025 annual result came in at $14.3 million, down 62.74% from the prior year.
• Other Non-Current Liabilities improved to $15.7 million in Q1 2026 per LKFT's latest filing, from $14.3 million in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for LKFT reached as high as $48.8 million in Q1 2024 and fell as low as $10.9 million in Q1 2022.
• A 5-year average of $28.4 million and a median of $27.5 million in 2025 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities soared 205.65% — and 2025, when it slumped 62.74%.
• Year by year, Other Non-Current Liabilities stood at $24.8 million in 2022, then soared by 44.76% to $35.9 million in 2023, then increased by 7.13% to $38.5 million in 2024, then plunged by 62.74% to $14.3 million in 2025, then gained by 9.4% to $15.7 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $15.7 million, $14.3 million, and $27.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.